Skip to main content
. 2020 Oct 27;18(11):535. doi: 10.3390/md18110535

Figure 3.

Figure 3

CFP promoted activation of human peripheral blood dendritic cells (PBDCs). Peripheral blood mononuclear cells (PBMCs) were treated with 100 μg/mL CFP and 100 μg/mL fucoidan. Six hours after treatment, the cells were harvested and the activation of blood dendritic cell antigen 1+ (BDCA1+) and BDCA3+ PBDCs was assessed. (A) Subsets of human PBDCs were defined as BDCA1+ and BDCA3+ cells in lineage−CD11c+ live leukocytes. (B) Expression levels of co-stimulators and MHC class I and II in BDCA1+ PBDCs (upper panel) and BDCA3+ PBDCs (lower panel). (C) Production levels of IL-6, IL-12, and TNF-α were measured in culture medium. All data are presented as averages and representative of six independent blood samples. ** p < 0.01.